Europe Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Country and Growth Forecast, 2023

List of Tables

The Europe Leukemia Therapeutics Market would witness market growth of 5.8% CAGR during the forecast period (2023-2029).

A rise in R&D spending has fueled the market's expansion due to the significant unmet medical demand for leukemia treatments that are more effective. Additionally, as a result of increased technological developments, like the creation of targeted and immunotherapies, there is an increase in demand for leukemia therapeutics that are efficient, which is propelling the market's expansion. Also, rising demand for combination medicines that might offer more thorough treatment modalities.

New combination therapies including chemotherapy and immunotherapy have been developed as a result of this. These factors are helping the market share to increase. Because of the accessibility of better healthcare infrastructure, rising unmet healthcare needs, rising incidences of chronic lymphocytic leukemia, and an upsurge in demand for leukemia therapeutics, the market is anticipated to grow at a rapid rate.

Additionally, the demand for superior health care is growing, the government is making sizable investments to upgrade the healthcare infrastructure, and the medical tourism sector is expanding rapidly in emerging economies. All of these factors are contributing to the rapid growth of the healthcare sector in these economies. The need for leukemia therapeutics is not just present in wealthy nations; it is also present in underdeveloped nations, which stimulates the market's expansion. Targeted therapy usage is increasing, and leukemia early diagnosis and treatment are becoming more well known, which contribute to the market's expansion.

The results of the 2021 Census show that England and Wales' overall population is still becoming older and that a larger proportion of people than ever are in older age groups. 18.6% of the population, or roughly 11 million people, were 65 years of age or older in 2016, an increase from 16.4% in the 2011 census. This includes 527,900 people, or more than 500,000, who were 90 years of age or older. The population's demographics changed between 2011 and 2021, as the median (average) age in England and Wales rose from 39 to 40 years. In Germany, about 25% of the population is over 60 or older, which is expected to climb. As a result, the number of cases of leukemia in the region is anticipated to rise along with the ageing population, which would raise the demand there.

The Germany market dominated the Europe Leukemia Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $775.4 million by 2029. The UK market is anticipated to grow at a CAGR of 4.9% during (2023 - 2029). Additionally, The France market would exhibit a CAGR of 6.6% during (2023 - 2029).

Based on Drug Class, the market is segmented into Targeted Therapy & Immunotherapy and Chemotherapy. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Type, the market is segmented into Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

Targeted Therapy & Immunotherapy
Chemotherapy

By Distribution Channel

Hospital Pharmacies
Drug Store & Retail Pharmacies
Online Providers

By Type

Chronic Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Chronic Myeloid Leukemia
Acute Myeloid Leukemia
Others

By Country

Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Companies Profiled

Gilead Sciences, Inc.
Bristol Myers Squibb Company
Sanofi S.A.
AbbVie, Inc.
Teva Pharmaceuticals Industries Ltd.
Lupin Limited
Amgen, Inc.
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Novartis AG

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Europe Leukemia Therapeutics Market, by Drug Class
- 1.4.2 Europe Leukemia Therapeutics Market, by Distribution Channel
- 1.4.3 Europe Leukemia Therapeutics Market, by Type
- 1.4.4 Europe Leukemia Therapeutics Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Product Launches and Product Expansions
- 3.2.3 Acquisition and Mergers
- 3.2.4 Approvals & Trails
3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May - 2022, Dec) Leading Players

Chapter 4. Europe Leukemia Therapeutics Market by Drug Class

4.1 Europe Targeted Therapy & Immunotherapy Market by Country
4.2 Europe Chemotherapy Market by Country

Chapter 5. Europe Leukemia Therapeutics Market by Distribution Channel

5.1 Europe Hospital Pharmacies Market by Country
5.2 Europe Drug Store & Retail Pharmacies Market by Country
5.3 Europe Online Providers Market by Country

Chapter 6. Europe Leukemia Therapeutics Market by Type

6.1 Europe Chronic Lymphocytic Leukemia Market by Country
6.2 Europe Acute Lymphocytic Leukemia Market by Country
6.3 Europe Chronic Myeloid Leukemia Market by Country
6.4 Europe Acute Myeloid Leukemia Market by Country
6.5 Europe Others Market by Country

Chapter 7. Europe Leukemia Therapeutics Market by Country

7.1 Germany Leukemia Therapeutics Market
- 7.1.1 Germany Leukemia Therapeutics Market by Drug Class
- 7.1.2 Germany Leukemia Therapeutics Market by Distribution Channel
- 7.1.3 Germany Leukemia Therapeutics Market by Type
7.2 UK Leukemia Therapeutics Market
- 7.2.1 UK Leukemia Therapeutics Market by Drug Class
- 7.2.2 UK Leukemia Therapeutics Market by Distribution Channel
- 7.2.3 UK Leukemia Therapeutics Market by Type
7.3 France Leukemia Therapeutics Market
- 7.3.1 France Leukemia Therapeutics Market by Drug Class
- 7.3.2 France Leukemia Therapeutics Market by Distribution Channel
- 7.3.3 France Leukemia Therapeutics Market by Type
7.4 Russia Leukemia Therapeutics Market
- 7.4.1 Russia Leukemia Therapeutics Market by Drug Class
- 7.4.2 Russia Leukemia Therapeutics Market by Distribution Channel
- 7.4.3 Russia Leukemia Therapeutics Market by Type
7.5 Spain Leukemia Therapeutics Market
- 7.5.1 Spain Leukemia Therapeutics Market by Drug Class
- 7.5.2 Spain Leukemia Therapeutics Market by Distribution Channel
- 7.5.3 Spain Leukemia Therapeutics Market by Type
7.6 Italy Leukemia Therapeutics Market
- 7.6.1 Italy Leukemia Therapeutics Market by Drug Class
- 7.6.2 Italy Leukemia Therapeutics Market by Distribution Channel
- 7.6.3 Italy Leukemia Therapeutics Market by Type
7.7 Rest of Europe Leukemia Therapeutics Market
- 7.7.1 Rest of Europe Leukemia Therapeutics Market by Drug Class
- 7.7.2 Rest of Europe Leukemia Therapeutics Market by Distribution Channel
- 7.7.3 Rest of Europe Leukemia Therapeutics Market by Type

Chapter 8. Company Profiles

8.1 Gilead Sciences, Inc.
- 8.1.1 Company overview
- 8.1.2 Financial Analysis
- 8.1.3 Research & Development Expenses
- 8.1.4 Recent strategies and developments:
  - 8.1.4.1 Partnerships, Collaborations, and Agreements:
  - 8.1.4.2 Acquisition and Mergers:
8.2 Bristol Myers Squibb Company
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
  - 8.2.5.1 Acquisition and Mergers:
  - 8.2.5.2 Partnerships, Collaborations and Agreements:
  - 8.2.5.3 Approvals and Trials:
8.3 Sanofi S.A.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Segmental and Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
  - 8.3.5.2 Trials and Approvals:
  - 8.3.5.3 Acquisitions and Mergers:
8.4 AbbVie, Inc.
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Acquisition and Mergers:
  - 8.4.5.2 Approvals & Trials:
8.5 Teva Pharmaceutical Industries Ltd.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Product Launches and Product Expansions:
8.6 Lupin Limited
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Recent strategies and developments:
  - 8.6.3.1 Product Launches and Product Expansions:
8.7 Amgen, Inc.
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Trials and Approvals:
8.8 Takeda Pharmaceutical Company Limited
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Approvals & Trials:
8.9 Pfizer, Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Regional & Segmental Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 Recent strategies and developments:
  - 8.9.5.1 Approvals & Trials:
  - 8.9.5.2 Acquisition and Mergers:
8.10. Novartis AG
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Research & Development Expense
- 8.10.4 Recent strategies and developments:
  - 8.10.4.1 Partnerships, Collaborations, and Agreements:
  - 8.10.4.2 Approvals & Trials:

LIST OF TABLES

TABLE 1 Europe Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 Europe Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Leukemia Therapeutics Market
TABLE 4 Product Launches And Product Expansions- Leukemia Therapeutics Market
TABLE 5 Acquisition and Mergers- Leukemia Therapeutics Market
TABLE 6 Approvals & Trials- Leukemia Therapeutics Market
TABLE 7 Europe Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 8 Europe Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 9 Europe Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 11 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 Europe Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 13 Europe Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 14 Europe Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 15 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 16 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 17 Europe Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 18 Europe Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 19 Europe Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 21 Europe Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 22 Europe Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 23 Europe Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 25 Europe Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 27 Europe Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 28 Europe Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 29 Europe Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 30 Europe Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 31 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 32 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 33 Europe Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 34 Europe Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 35 Germany Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 36 Germany Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 37 Germany Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 38 Germany Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 39 Germany Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 40 Germany Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 41 Germany Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 42 Germany Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 43 UK Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 44 UK Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 45 UK Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 46 UK Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 47 UK Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 UK Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 49 UK Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 50 UK Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 51 France Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 52 France Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 53 France Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 54 France Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 55 France Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 56 France Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 57 France Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 58 France Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 59 Russia Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 60 Russia Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 61 Russia Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 62 Russia Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 63 Russia Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 64 Russia Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 65 Russia Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 66 Russia Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 67 Spain Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 68 Spain Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 69 Spain Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 70 Spain Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 71 Spain Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 72 Spain Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 73 Spain Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 74 Spain Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 75 Italy Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 76 Italy Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 77 Italy Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 78 Italy Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 79 Italy Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 80 Italy Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 81 Italy Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 82 Italy Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 83 Rest of Europe Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 84 Rest of Europe Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 85 Rest of Europe Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 86 Rest of Europe Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 87 Rest of Europe Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 88 Rest of Europe Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 89 Rest of Europe Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 90 Rest of Europe Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 91 Key Information - Gilead Sciences, Inc.
TABLE 92 Key Information - Bristol Myers Squibb Company
TABLE 93 Key Information - Sanofi S.A.
TABLE 94 Key information - AbbVie, Inc.
TABLE 95 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 96 Key Information - Lupin Limited
TABLE 97 Key Information - Amgen, Inc.
TABLE 98 Key Information - Takeda Pharmaceutical Company Limited
TABLE 99 Key Information - Pfizer, Inc.
TABLE 100 Key Information - Novartis AG

List of Figures

FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May - 2022, Dec) Leading Players
FIG 5 Europe Leukemia Therapeutics Market Share by Drug Class, 2022
FIG 6 Europe Leukemia Therapeutics Market Share by Drug Class, 2029
FIG 7 Europe Leukemia Therapeutics Market by Drug Class, 2019 - 2029, USD Million
FIG 8 Europe Leukemia Therapeutics Market Share by Distribution Channel, 2022
FIG 9 Europe Leukemia Therapeutics Market Share by Distribution Channel, 2029
FIG 10 Europe Leukemia Therapeutics Market by Distribution Channel, 2019 - 2029, USD Million
FIG 11 Europe Leukemia Therapeutics Market Share by Type, 2022
FIG 12 Europe Leukemia Therapeutics Market Share by Type, 2029
FIG 13 Europe Leukemia Therapeutics Market by Type, 2019 - 2029, USD Million
FIG 14 Europe Leukemia Therapeutics Market Share by Country, 2022
FIG 15 Europe Leukemia Therapeutics Market Share by Country, 2029
FIG 16 Europe Leukemia Therapeutics Market by Country, 2019 - 2029, USD Million
FIG 17 Recent strategies and developments: Gilead Sciences, Inc.
FIG 18 Recent strategies and developments: Bristol Myers Squibb Company
FIG 19 Recent strategies and developments: Sanofi S.A.

Europe Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Country and Growth Forecast, 2023 - 2029

Description

Table of Contents